Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biovaxys Technology Corp (LMNGF)

Biovaxys Technology Corp (LMNGF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LMNGF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2309 +4.16%
on 04/21/21
0.3860 -37.69%
on 03/22/21
-0.1345 (-35.87%)
since 03/19/21
3-Month
0.1401 +71.66%
on 01/22/21
0.6200 -61.21%
on 02/16/21
+0.1005 (+71.79%)
since 01/21/21

Most Recent Stories

More News
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) "BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study

and , /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) "BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of , has initiated...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

, /PRNewswire/ -- BioVaxys Technology Corp. ("BioVaxys" or "the Company") is pleased to announce that , MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A,...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
AWH : 5.90 (+3.51%)
BVAXF : 0.1780 (-3.78%)
Why 'Killer' T Cells Could Boost COVID Immunity In Face Of New Variants

PALM BEACH,  Fla., /PRNewswire/ -- In the race against emerging coronavirus variants, researchers are looking beyond antibodies for clues to lasting protection from COVID-19. Concerns about coronavirus...

BIOV.CN : 0.220 (-4.35%)
LMNGF : 0.2405 (-7.00%)
AGEN : 5.45 (+1.30%)
BMY : 65.85 (+0.90%)
NVAX : 192.48 (+0.12%)
ONTX : 7.43 (+4.65%)
GSK : 39.70 (-0.38%)
VIR : 49.59 (+5.29%)
BioVaxys Announces Appointment of Policy Advisor

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) "BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
BioVaxys Announces Uplisting To The OCTQB Venture Market

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies

, /PRNewswire/ -- Ovarian cancer is the 8th most common cancer among women and ranks 5th in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system....

BIOV.CN : 0.220 (-4.35%)
LMNGF : 0.2405 (-7.00%)
CTXR : 3.94 (-1.01%)
BMY : 65.85 (+0.90%)
RHHBY : 46.6000 (+1.02%)
AZN : 58.42 (+0.76%)
BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF"BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)
BioVaxys Assigned "BVAXF" By Finra As New US OTC Trading Symbol

and , /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) "BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced that effective...

LMNGF : 0.2405 (-7.00%)
BIOV.CN : 0.220 (-4.35%)
BVAXF : 0.1780 (-3.78%)

Key Turning Points

3rd Resistance Point 0.2921
2nd Resistance Point 0.2780
1st Resistance Point 0.2592
Last Price 0.2405
1st Support Level 0.2263
2nd Support Level 0.2122
3rd Support Level 0.1934

See More

Last Price 0.2405
52-Week High N/A
Fibonacci 61.8% 0.4007
Fibonacci 50% 0.3330
Fibonacci 38.2% 0.2653
52-Week Low N/A

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar